Find Clinical Trials | Cedars-Sinai

354 results found

Ovary

Olaparib With or Without Bevacizumab in BRCA 1/2 Mutated or Homologous Recombination Deficient Ovarian Cancer

This study focuses on people with ovarian cancer who have tested positive for BRCA1/2 mutation (change or defect in the BRCA gene) or homologous recombination deficiency (when the body cannot repair breaks in DNA). The ...

Breast

Low-Dose Tamoxifen in Low-Risk, Early-Stage Breast Cancer

Hormone receptor-positive breast cancer is the most common type of breast cancer, and 5+ years of hormone therapy is the mainstay of the treatment. However, many patients experience side effects from the medications, and some ...

Lung

Amgen, 20230153, Ph 2, randomized, open-label, NSCLC, AMG193

Primary Objective: To characterize safety and efficacy of 2 dose levels of AMG 193 by investigator.

Esophagus, Larynx, Lip, Oral Cavity and Pharynx, Lung, Melanoma

Pfizer Inc, C5901001, Ph 1, Open-Label, Multi-Center, Melanoma, Solid Tumor, PF-08046031

Primary -To characterize the safety and tolerability profile of PF-08046031 in participants with advanced melanomas and select solid tumors (Parts 1, 2, 3) -To identify the MTD or MAD of PF-08046031 (Part 1) -To identify a recommended dose for ...

Leukemia, other

MM1YA-CTG01, Ph2, Open, Randomized, Venetoclax + chemotherapy, AML

Primary Objective: To compare the rates of undetectable measurable residual disease (MRD) in patients who achieve a Complete Remission (CR) after induction therapy with 7 +3 (cytarabine + daunorubicin) vs. azacitidine + venetoclax vs. 7+3 + ...